Recently, Nature reported that 15 antibody suppliers and more than 18,000 antibody validation images contain suspicious issues, once again bringing the “ Commercial Antibody Reliability “has been thrust into the spotlight.”

Most of the online discourse revolves around “manufacturer fraud and industry chaos,” but we aim to rise above public sentiment and, from the perspective of scientific research’s underlying logic, examine several structural issues in the sector that are seldom brought to light. As a long-time industry veteran… Gene Knockout (KO) Cell Models and Antibody Validation From a technical standpoint, we remain neutral in our post‑mortem analysis: this debacle has exposed far more than just a few compromised images.

 

01 What’s collapsing isn’t an image—it’s a failed “self‑validating” business model.

Most people have labeled this incident a “fraud scandal,” but the deeper truth is that the industry model relying on manufacturers’ self‑certification has utterly collapsed.

Many people have never clarified a crucial point: the WB validation images posted on antibody company websites are, in essence, not traceable raw research data, but rather… Marketing materials aimed at closing deals 。

The core objectives of marketing materials are aesthetics, consistency, and strong persuasiveness; in contrast, the essence of scientific data lies in its authenticity, originality, and reproducibility. When, for decades, the industry has tacitly equated “marketing graphics” with “proof of quality,” resorting to photo editing, visual enhancement, and selective presentation is no longer merely a matter of individual corporate ethics—it is an inevitable outcome of the prevailing business model.

This large-scale exposé has merely laid bare the industry’s longstanding vulnerabilities: In the past, we have consistently “defaulted to trusting vendor self‑certification” rather than “relying on empirical evidence from experiments.”

Following this incident, the industry’s trust framework has been irreversibly rewritten: Suppliers are no longer deemed trustworthy, and the responsibility for antibody validation has officially shifted back to the research community and independent third-party verification.

 

02 Long-term misalignment in the industry: What you’re buying is integration capability, but what you really need is specificity.

Beyond the controversy lies a more deeply entrenched pain point in scientific research.

The core needs of researchers regarding antibodies: Absolute specificity — Only the target protein is recognized, with no nonspecific bands and no cross-reactivity.

Core parameters of commercial antibody sales: Combined ability — The ability to match a particular sample band does not provide rigorous proof of target specificity.

For decades, the yawning gap between the two has been “forced” to close by nothing more than a series of official website verification images. With the credibility of those images now shattered, the chasm has been laid bare.

Even before this incident, A large-scale 2023 eLife study has confirmed that 614 mainstream commercial antibodies, More than half fail to meet the officially claimed specific performance. 。

This means: That antibodies are unreliable is nothing new; it’s just that image manipulation has brought this widespread issue into the spotlight.

All researchers should recognize one reality: The specificity of an antibody is never bought—it is earned through painstaking, hands-on validation.

 

03 Facing the Gold Standard of KO: It’s Tough, But Far From All-Purpose

In the industry, gene‑knockout (KO) cell models are widely recognized as the gold standard for robust negative controls in antibody validation.

The principle is straightforward: once the target protein has been completely knocked out, the specific antibody should yield no band and no signal. Compared with positive results that are prone to fabrication and embellishment, Evidence of the absence of a negative finding carries the highest level of evidentiary weight. 。

As the technical provider of high‑frequency KO cell models, we would like to offer an objective and neutral reminder: “Performed a KO” does not equal “validated as effective.” Moreover, using a crude KO control can actually lead to misleading experimental conclusions. The industry commonly faces three hidden pitfalls:

1. Gene knockout does not necessarily mean complete loss of the protein.

When an indel occurs near the 3′ end, it may preserve an N‑terminal epitope, resulting in a truncated protein with a C‑terminal deletion. A band is detectable by Western blotting, but the protein is completely inactive. Based solely on the band, it is impossible to distinguish whether the signal arises from non‑specific antibody binding or from residual truncated protein.

2. Isomers and family proteins can easily interfere with validation results.

Most genes give rise to multiple transcript isoforms; if an sgRNA knocks out only a single exon, only part of the epitope is lost, and the functional protein may still be expressed. What appears to validate the antibody is, in fact, merely evidence of a design flaw.

3. The family compensation effect can easily lead to misjudgments.

Following knockout of the target protein, homologous family proteins are upregulated as a compensatory response, giving rise to new spurious bands that can easily be misinterpreted as antibody cross-reactivity.

Therefore, we have always adhered to: The value of a KO lies not in the “knockout action” itself, but in its rigorous design, multi‑tiered validation, and traceable data pipeline.

A truly qualified KO validation must be confirmed across genomic, transcriptomic, and proteomic dimensions, rather than simply delivering a single “knockout cell line.”

04 A New Industry Standard Has Been Established: From Trusting Brands to Trusting Evidence

What this controversy has truly changed is not the antibody products themselves, but rather… Procurement and Evaluation Logic for Research Reagents 。

In the past: prioritizing big brands, trusting official website images, and assuming manufacturer endorsements.

Now and in the Future: Brands are ineffective, images are invalid—only empirical evidence matters.

 

We believe that the research group’s antibody validation guidelines will shift comprehensively toward three principles:

1. Antibodies without negative control data from KO assays will no longer be prioritized.

Manufacturer‑generated images are entirely unreliable; only independent, reproducible negative data from knockout cells can demonstrate genuine specificity.

2. Prioritize the use of literature‑derived, rigorously controlled antibodies.

Antibodies with publicly available KO/KD validation papers, traceable batch numbers, and complete RRID information are far more reliable than those from manufacturers’ new‑product images.

3. For challenging targets, employ a genomic tagging strategy as a fallback approach.

For challenging targets that are low-abundance, readily degradable, and lack high-quality antibodies, endogenous tag knock-in enables gene‑level specification of assay specificity, thereby overcoming the antibody‑dependency bottleneck.

 

In closing: the industry will ultimately return to an evidence-based approach.

The exposure of these 18,000 problematic images was the result of a postdoctoral researcher’s automated screening process, rather than industry standards or regulatory mechanisms. This very fact underscores: The industry has long relied on self-regulation, lacking institutionalized empirical standards.

We always maintain a neutral stance: We do not deny the scientific value of antibodies, nor do we jump on trends to criticize the industry.

Antibodies remain a core, high‑frequency tool in the life sciences. However, the accuracy of these tools must be underpinned by an independent, rigorous, and traceable experimental framework.

Antibodies are responsible for “detecting proteins,” while knockout validation is used to “confirm or refute” the findings.

As the industry transitions from “manufacturer self-certification” to “third-party verification,” what we can do is continue to provide Identifiable, verifiable, unaltered, and traceable. A gene-edited cellular model that provides a reliable research benchmark for every antibody validation.

If you are evaluating the reliability of your antibody and require rigorous validation with a KO negative control, feel free to reach out for discussion.

 

References

1. Garisto D. More than 18,000 questionable images found in antibody catalogues of 15 companies. Nature News, 2026.

2. Uhlén M, et al. A proposal for validation of antibodies. Nature Methods, 2016.

3. Large-scale evaluation of 614 commercial antibodies. eLife, 2023.